Live market news
Stocks
KOD

Kodiak Sciences Inc.

KODStockUnited States

See in Charts

Latest news on KODranked by Oyticker for market impact

75Impact
NeutralMajor information28 Sept 2026 · 00:14 UTC · Global · Medium term
Kodiak Sciences to release DAYBREAK Phase 3 topline results for wet AMD candidates on September 28, 2026
Kodiak Sciences (KOD) will present topline data from its DAYBREAK pivotal Phase 3 study evaluating Zenkuda and KSI-501 in wet age-related macular degeneration on September 28, 2026. This is a material clinical milestone for a precommercial retina-focused biotech.
KODBiotechnologyPharmaceuticalsOphthalmology

SEC filings

What KOD filed

All its filings

28 Sept 2026
Other event (opens the document on sec.gov)8-K
13 Aug 2026
Quarterly report (opens the document on sec.gov)10-Q
13 Aug 2026
Results announced (opens the document on sec.gov)8-K
4 Jun 2026
Shareholder vote results (opens the document on sec.gov)8-K

From SEC EDGAR, the public record of what US-listed companies file. Each document opens on sec.gov.

Oyticker provides market information and analysis for educational purposes. It is not investment advice: you remain responsible for your own decisions.

Latest news on KODranked by Oyticker for market impact

Kodiak Sciences to release DAYBREAK Phase 3 topline results for wet AMD candidates on September 28, 2026

What KOD filed